4.8 Article

Battlefield against hepatitis B infection and HCC in Africa

Journal

JOURNAL OF HEPATOLOGY
Volume 66, Issue 3, Pages 645-654

Publisher

ELSEVIER
DOI: 10.1016/j.jhep.2016.10.013

Keywords

HBV; HCC; Cirrhosis; HCC; Treatment; Immunization; Africa; Global health; Antiviral agents

Funding

  1. European Commission (FP7)
  2. Gilead USA Company

Ask authors/readers for more resources

Despite effective and safe hepatitis B virus (HBV) vaccine and antiviral therapies, HBV-related hepatocellular carcinoma (HCC) remains a major cause of deaths in young adults in Africa. There are multiple barriers to control the burden of HBV infection and HCC. In comparison to other major infectious diseases, HBV infection and liver diseases have received remarkably little attention from the global health community. There is an urgent need to improve birth dose vaccine coverage and implementing screening and treatment interventions. This requires a dramatic simplification of the management of chronic hepatitis B in Africa, with access to reliable, robust and inexpensive diagnostic tools and strong support from the local governments and the international health community. This review analyses 1) the characteristics of HBV hepatitis and HCC epidemics in Africa and 2) the barriers and potential solutions to control it. (C) 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available